CAMBRIDGE, Mass., March 03, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU). The trial is designed to evaluate the safety and pharmacokinetics of RTX-134 in adult patients with PKU. “Phenylketonuria is a devastating metabolic disorder that can lead to serious cognitive impairment if not properly treated,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius.

BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.

We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September 30th. In this article, we look at what those funds think of Rubius Therapeutics, Inc. (NASDAQ:RUBY) based on that […]

Rubius Therapeutics, Inc. (RUBY) a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported fourth quarter and full-year 2019 financial results and announced its plan to focus on the development of its oncology and autoimmunity pipeline. This strategic decision allows Rubius to focus on the areas in which its RED PLATFORM® may offer the greatest potential to benefit patients. Development in these therapeutic areas is enabled by the Company’s investment in internal manufacturing at its Smithfield, RI facility, which is now cGMP ready to produce clinical supply for its lead oncology program, RTX-240, a broad immunostimulatory Red Cell Therapeutic™ for the treatment of solid tumors.

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced 2020 objectives and operational updates. Pablo J. Cagnoni, M.D., chief executive officer, will present these updates and review 2019 accomplishments today at 9:00 a.m. PST / 12:00 p.m. EST at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is engineered to mimic the human immune system by stimulating adaptive and innate immunity to generate an anti-tumor immune response. “We are excited to advance our first-ever oncology Red Cell Therapeutic, RTX-240, into clinical development and to increase our understanding of its potential to help cancer patients,” said Christina Coughlin, M.D., Ph.D., chief medical officer of Rubius Therapeutics.

Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors.

CAMBRIDGE, Mass., May 26, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

CAMBRIDGE, Mass., May 15, 2020 -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

CAMBRIDGE, Mass., May 04, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

CAMBRIDGE, Mass., April 29, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to.

The CEO of a Cambridge biotech startup promised the company would “deliver in 2020” after announcing a second delay with its first-ever clinical trial.

Even if it's not a huge purchase, we think it was good to see that Pablo Cagnoni, the CEO, President & Director of...

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a new viral vector platform based on its groundbreaking work on the human commensal virome. Ring's technology promises to address many of the limitations of current DNA and gene therapies, such as limited access to diverse tissues, inability to redose, risk of genomic integration, and poor tolerability. Ring's founding and continued development are resourced by an initial capital commitment of $50 million from Flagship Pioneering.

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Christina Coughlin, M.D., Ph.D., as the Company’s chief medical officer, effective January 6, 2020. With Dr. Coughlin’s appointment, Chris Carpenter, M.D., Ph.D., Rubius’ previous chief medical officer, is transitioning to a scientific advisory role.

Rubius Therapeutics, Inc. (RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020. Dr. Turka, a distinguished physician-scientist in autoimmunity and translational immunology, joins Rubius from Rheos Medicines, where he was a co-founder and served as chief scientific officer. “Larry brings to Rubius exceptional insights and an extraordinary record of scientific achievement in immune-mediated diseases,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics.

CAMBRIDGE, Mass., May 12, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

CAMBRIDGE, Mass., Jan. 02, 2020 -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create.

Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.